Earnings ·
Akari Therapeutics reported second quarter 2026 financial results and highlighted operational progress
AKTXAkari Therapeutics Plc
Akari Therapeutics reported second quarter 2026 financial results and highlighted operational progress. The company raised approximately $8.6 million in gross proceeds through a private placement of $5.5 million and warrant exercises worth $3.1 million, resulting in net proceeds of approximately $8.0 million. Research and development expenses increased to $2.1 million from $0.7 million in the prior year period, while general and administrative expenses remained stable at $2.5 million. The company reported a net loss of $4.8 million compared to $1.9 million previously. Cash reserves stood at $7.7 million as of June 30, 2026. Akari Therapeutics is an oncology biotechnology company developing antibody drug conjugates with a novel RNA splicing-targeting payload.